



RECAP

— ENHANCED CONTENT, ANALYTICS, AND VISUALIZATION TOOLS

Whether you are looking to buy, sell, or license a drug candidate, our gold standard biopharma deals intelligence gives you insight to support your own deals. Thomson Reuters Recap offers you rapid insight into critical deal-making trends and allows you to uncover nuances in specific deal types.

USE RECAP TO:

- Determine how much an asset is worth
- Evaluate the right time to license your asset in the drug development process
- Identify ideal partners for the best alliance
- Determine which type of transaction is best for you
- Compare market-based deal terms for different types of transactions

Search for potential partners, conduct due diligence, assess deal value, explore deal structures and terms, and determine statistical technical success rates. From broad marketwide trends to tightly focused comparables, Recap helps you make better decisions faster.

ABOUT RECAP

Recap from Thomson Reuters aims to provide analysis and advice for biopharmaceutical business development. Recap clients include biotechnology and pharmaceutical companies, universities, investment banking, and venture firms.

More than 1,500 organizations utilize Recap's data services. Recap combines extensive deals analysis experience with the breadth of Life Sciences service offerings from Thomson Reuters creating a powerful combination for clients.

A UNIQUE SOURCE OF UNREDACTED CONTRACTS

Easily analyze partnering options, deal structures, and asset values based on the deepest available data. Recap features more than 40,000 deal records that are updated daily, including press releases, SEC-filed contracts, and clinical trials data. Unredacted contracts, acquired through FOIA requests, give you a complete view into the commercial details, including post-commercialization royalty rates.

An intuitive interface and superior analytics enable you to quickly make informed decisions based on data that is highly specific to your needs. We believe that the best deals and pipelines depend on the best data. See for yourself the difference that deep deal and pipeline data can make on your business.

ENHANCE YOUR EXPERIENCE WITH CONTENT, VISUALIZATIONS, AND ANALYTICS TOOLS

These tools can help you derive further insights from the Recap information with powerful and intuitive visualizations and analytics.



DEAL BUILDER

Deals are typically subordinate to strategic plans that include revenue, control, and timing goals. With Deal Builder, the core of Recap, you can:

- Identify deal comparables, deal structure alternatives, and critical deal terms
- Locate potential partnership opportunities and conduct due diligence

Data and Analytics:

- 49,000+ Alliance Summaries
- 2,200+ Contract Analyses
- 1,700+ Deal Snapshots
- 362 index criteria
- 15,800+ licensees and licensors
- Custom Excel® reports
- 29,000+ contracts

DEAL BUILDER SELECT

Gain further ground on your deal with Deal Builder Select. Available as part of your Recap IQ subscription, Deal Builder Select helps you easily:

- Find precise comparables
- Understand a set of deals in minutes, not hours
- Create your own custom analytics

Data and Analytics:

- Smart Summaries that provide the best “decoded” analysis of announced deals available
- 12 key data fields that have been re-indexed with new values to retrieve precise result sets
- New standardized Deal Snapshot that utilizes new high-quality data fields, including updated financial fields
- Enhanced Excel reports, including presentation tables, user-defined pivot tables, and graphical analysis of key financials
- 49 new data fields in the Alliance Summary, including product names, mechanisms of action, asset type, and M&A data related to the target company
- 34 updated fields, including all financial payments, licensees and licensors, transaction types, and Deal Subject

VALUATION ANALYZER

Deal terms for commercialized products can be difficult to come by and difficult to analyze. The additional Recap analytics module, Valuation Analyzer, provides you with ready analysis of and insights into our collection of 2,600+ deals with unredacted SEC contracts. A proprietary algorithm calculates effective royalty rates that enable you to compare disparate deals with varying royalty rates, transfer prices, and profit splits at the \$200M, \$500M, and \$1B sales levels.

- Compare deals to find market rates for royalties, transfer prices, and profit splits
- Find critical deal terms from unredacted contracts

Data and Analytics:

- 2,600+ Alliance Summaries and contracts
- 1,100+ Contract Analyses
- 382 index criteria
- Custom Excel reports

DEVELOPMENT OPTIMIZER

Available separately or as part of your Recap subscription, Development Optimizer uses highly curated pipeline data from 321 leading biotech companies. You can estimate a drug’s probability of success, compare attrition advancement rates and reasons for termination, and determine which drugs are unpartnered.

- Study and compare attrition and advancement rates and reasons for termination
- Identify potential partners based on development and regulatory performance

Data and Analytics:

- 2,800+ project records, updated daily
- 7,900+ clinical trials correlated with results, regulatory status, and review times
- 20,700+ corporate press releases
- Graphical and tabular development timelines with detailed milestone information
- 210 index criteria

Visit ip-science.thomsonreuters.com for more information.

AMERICAS

North America: +1 800 336 4474
+1 215 386 0100

Latin America: +55 11 8370 9845

EMEA

Barcelona: +34 93 459 2220

London: +44 20 7433 4000

ASIA PACIFIC

Singapore: +65 6775 5088

Tokyo: +81 3 5218 6500

For a complete office list visit:
[ip-science.thomsonreuters.com/
contact](http://ip-science.thomsonreuters.com/contact)

LS 201307
1.2016

Copyright © 2016 Thomson Reuters



THOMSON REUTERS™